Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients
- PMID: 35869852
- DOI: 10.1093/cid/ciac588
Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients
Conflict of interest statement
Potential conflicts of interest. R. J. reports consulting fees paid to the author as a clinical consultant for online content from Wolters-Kluwer textbook company. S. D. reports unpaid participation on Data Safety Monitoring Board or Advisory Board for HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A randomized, double-blind, placebo-controlled trial. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment in
-
Reply to Pesko et al.Clin Infect Dis. 2022 Nov 30;75(11):2050. doi: 10.1093/cid/ciac589. Clin Infect Dis. 2022. PMID: 35869851 No abstract available.
Comment on
-
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.Clin Infect Dis. 2023 Feb 8;76(3):e342-e349. doi: 10.1093/cid/ciac443. Clin Infect Dis. 2023. PMID: 35653428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources